The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients
Open accessAbstract
OBJECTIVE: To investigate the pathophysiologic mechanism of encephalopathy and prolonged comatose or stuporous state in severally ill patients with coronavirus disease 2019 (COVID-19). METHODS: Eight COVID-19 patients with signs of encephalopathy were tested for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the serum and CSF using a Food and Drug Administration-approved and independently validated ELISA. Blood-brain barrier (BBB) integrity and immunoglobulin G (IgG) intrathecal synthesis were further tested using albumin and IgG indices. The CSF was also tested for autoimmune encephalitis antibodies and 14-3-3, a marker of ongoing neurodegeneration. RESULTS: All patients had anti-SARS-CoV-2 antibodies in their CSF, and 4 of 8 patients had high titers, comparable to high serum values. One patient had anti-SARS-CoV-2 IgG intrathecal synthesis, and 3 others had disruption of the blood-brain barrier. The CSF in 4 patients was positive for 14-3-3-protein suggesting ongoing neurodegeneration. In all patients, the CSF was negative for autoimmune encephalitis antibodies and SARS-CoV-2 by PCR. None of the patients, apart from persistent encephalopathic signs, had any focal neurologic signs or history or specific neurologic disease. CONCLUSIONS: High-titer anti-SARS-CoV-2 antibodies were detected in the CSF of comatose or encephalopathic patients demonstrating intrathecal IgG synthesis or BBB disruption. A disrupted BBB may facilitate the entry of cytokines and inflammatory mediators into the CNS enhancing neuroinflammation and neurodegeneration. The observations highlight the need for prospective CSF studies to determine the pathogenic role of anti-SARS-CoV-2 antibodies and identify early therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Blood-brain barrier disruption is associated with encephalopathy, favoring the neuro-inflammation theory.
“Several studies implied that blood–brain barrier disruption is associated with encephalopathy, favoring the neuro-inflammation theory [150, 151].”
From Cognitive decline following acute viral infections: literature review and projections for post-COVID-19 (2022) · cites this paper as [150]
CSF analysis of patients with neurological symptoms showed SARS-CoV-2 immunoreactivity resulting from serum antibody leakage to the CSF rather than intrathecal antibody production.
“CSF analysis of patients with neurological symptoms showed SARS-CoV-2 immunoreactivity, resulting from serum antibody leakage to the CSF, rather than to intrathecal antibody production [150, 160].”
From Cognitive decline following acute viral infections: literature review and projections for post-COVID-19 (2022) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A first case of meningitis/encephalitis associated with SARS-Coronavirus-2
Moriguchi, T., Harii, N., Goto, J., Harada, D., Sugawara, H., Takamino, J., Ueno, M., Sakata, H., Kondo, K., Myose, N., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.062 · Cited by 2,024
Multiorgan and Renal Tropism of SARS-CoV-2
Puelles, V. G., Lütgehetmann, M., Lindenmeyer, M. T., Sperhake, J. P., Wong, M. N., Allweiss, L., Chilla, S., Heinemann, A., Wanner, N., Liu, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2011400 · Cited by 1,775 · cited 2×
“The CSF was also tested for (1) SARS-CoV-2 genetic determination with PCR; (2) autoimmune encephalitis autoantibodies, including antiNMDAr, AMPAr, GABAbr, CASPR2, DPPX, and LGI1, using a cell-based assay (Euroimmun); and (3) for 14-3-3 protein, a marker of neurodegeneration, using Western Blot and an anti-14-3-3 polyc…”
MethodStringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
Zubair, A. S., McAlpine, L. S., Gardin, T., Farhadian, S., Kuruvilla, D. E., & Spudich, S. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2065 · Cited by 923
COVID ‐19: A Global Threat to the Nervous System
Koralnik, I. J., & Tyler, K. L. (2020) · Annals of Neurology · doi:10.1002/ana.25807 · Cited by 480
Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19
Kanberg, N., Ashton, N. J., Andersson, L., Yilmaz, A., Lindh, M., Nilsson, S., Price, R. W., Blennow, K., Zetterberg, H., & Gisslén, M. (2020) · Neurology · doi:10.1212/wnl.0000000000010111 · Cited by 373
Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease
Dalakas, M. C. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000781 · Cited by 257
Self-citationStatus of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke
Saiegh, F. A., Ghosh, R., Leibold, A. T., Avery, M. B., Schmidt, R. F., Theofanis, T. N., Mouchtouris, N., Philipp, L. R., Peiper, S. C., Wang, Z., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323522 · Cited by 254
Benussi, A., Pilotto, A., Premi, E., Libri, I., Giunta, M., Agosti, C., Alberici, A., Baldelli, E., Benini, M., Bonacina, S., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009848 · Cited by 238
Macrophages: a Trojan horse in COVID-19?
Park, M. D. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0317-2 · Cited by 165
Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2–associated encephalitis
Bodro, M., Compta, Y., Llansó, L., Esteller, D., Cubero, A. D.-M., Mesa, A., Rodríguez, A. H., Sarto, J., Martínez‐Hernández, E., Vlagea, A. D., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000821 · Cited by 72
A map of SARS-CoV-2 and host cell interactions
Malle, L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0318-1 · Cited by 33
Flagged first, then by citations
Cited by
Sorted by citations
The neurobiology of long COVID
Monje, M., & Iwasaki, A. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.006 · Cited by 415
Song, E., Bartley, C. M., Chow, R. D.-W., Ngo, T. T., Jiang, R., Zamecnik, C. R., Dandekar, R., Loudermilk, R. P., Dai, Y., Liu, F., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100288 · Cited by 219
Cerebral dysfunctions caused by sepsis during ageing
Manabe, T., & Heneka, M. T. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00643-7 · Cited by 191
Heming, M., Li, X., Räuber, S. J., Mausberg, A. K., Börsch, A., Hartlehnert, M., Singhal, A., Lu, I., Fleischer, M., Szepanowski, F., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.12.011 · Cited by 181
COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis
Soung, A., Vanderheiden, A., Nordvig, A. S., Sissoko, C. A., Canoll, P., Mariani, M. B., Jiang, X., Bricker, T. L., Rosoklija, G. B., Arango, V., et al. (2022) · Brain · doi:10.1093/brain/awac270 · Cited by 278
Cerebrospinal fluid in COVID-19: A systematic review of the literature
Lewis, A. K., Frontera, J. A., Placantonakis, D. G., Lighter, J., Galetta, S. L., Balcer, L. J., & Melmed, K. R. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117316 · Cited by 165
Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease
Balcom, E. F., Nath, A., & Power, C. (2021) · Brain · doi:10.1093/brain/awab302 · Cited by 163
Jarius, S., Pache, F. C., Körtvelyessy, P., Jelčić, I., Stettner, M., Franciotta, D. M., Keller, E., Neumann, B. H., Ringelstein, M., Şenel, M., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02339-0 · Cited by 159
Dalakas, M. C., & Spaeth, P. J. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286421997381 · Cited by 126
Self-citationCOVID-19 and psychosis risk: real or delusional concern?
Watson, C. J., Thomas, R. H., Solomon, T., Michael, B. D., Nicholson, T. R., & Pollak, T. A. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135491 · Cited by 103
Damiano, R. F., Guedes, B. F., de Rocca, C. C., de Pádua Serafim, A., Castro, L. H. M., Munhoz, C. D., Nitrini, R., Filho, G. B., Miguel, E. C., Lucchetti, G., et al. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01286-4 · Cited by 98
Inflammation at the crossroads of COVID-19, cognitive deficits and depression
Silva, N. M. L. E., Barros‐Aragão, F. G. Q., Felice, F. G. D., & Ferreira, S. T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109023 · Cited by 96
Versace, V., Sebastianelli, L., Ferrazzoli, D., Romanello, R., Ortelli, P., Saltuari, L. L., D’Acunto, A., Porrazzini, F., Ajello, V., Oliviero, A., et al. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.03.001 · Cited by 95
Zamani, R., Pouremamali, R., & Rezaei, N. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0082 · Cited by 80
Neuropsychiatric complications of covid-19
Butler, M., Pollak, T. A., Rooney, A. G., Michael, B. D., & Nicholson, T. R. (2020) · BMJ · doi:10.1136/bmj.m3871 · Cited by 85
Can Melatonin Be a Potential “Silver Bullet” in Treating COVID-19 Patients?
Cardinali, D. P., Brown, G. M., & Pandi-Perumal, S. R. (2020) · Diseases · doi:10.3390/diseases8040044 · Cited by 82
Garcia, M. A., Barreras, P., Lewis, A., Pinilla-Monsalve, G. D., Sokoll, L. J., Kickler, T. S., Mostafa, H. H., Caturegli, M., Moghekar, A., Fitzgerald, K. C., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117517 · Cited by 81
Inflammatory leptomeningeal cytokines mediate COVID-19 neurologic symptoms in cancer patients
Remsik, J., Wilcox, J. A., Babady, N. E., McMillen, T. A., Vachha, B. A., Halpern, N. A., Dhawan, V., Rosenblum, M., Iacobuzio-Donahue, C. A., Avila, E. K., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.007 · Cited by 77
Review of organ damage from COVID and Long COVID: a disease with a spectrum of pathology
Ewing, A. G., Šalamon, Š., Pretorius, E., Joffe, D., Fox, G., Bilodeau, S., & Yaneer Bar-yam, A. (2024) · Medical Review · doi:10.1515/mr-2024-0030 · Cited by 65
Han, Y., Yuan, K., Wang, Z., Liu, W., Lu, Z.-A., Liu, L., Shi, L., Yan, W., Yuan, J., Li, J., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01629-8 · Cited by 67
Shen, W., Elahi, M., Logue, J., Yang, P., Baracco, L., Reece, E. A., Wang, B., Li, L., Blanchard, T. G., Han, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.31.478476 · Cited by 59
Neuroimmune disorders in COVID-19
Ariño, H., Heartshorne, R., Michael, B. D., Nicholson, T. R., Vincent, A. C., Pollak, T. A., & Vogrig, A. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11050-w · Cited by 57
Bartley, C. M., Johns, C., Ngo, T. T., Dandekar, R., Loudermilk, R. P., Alvarenga, B. D., Hawes, I. A., Zamecnik, C. R., Zorn, K. C., Alexander, J. R., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3821 · Cited by 55
What SARS-CoV-2 does to our brains
Aschman, T., Mothes, R., Heppner, F. L., & Radbruch, H. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.013 · Cited by 50
Dalakas, M. C., Bitzogli, K., & Alexopoulos, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627285 · Cited by 42
Self-citationImplementation of blood-brain barrier on microfluidic chip: Recent advance and future prospects
Bi, W., Cai, S., Lei, T., & Wang, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101921 · Cited by 44
de Andrade, E. G., Šimončičová, E., Carrier, M., Vecchiarelli, H. A., Robert, M.-È., & Tremblay, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.647378 · Cited by 39
COVID-19 Immunobiology: Lessons Learned, New Questions Arise
Kaklamanos, A., Belogiannis, K., Skendros, P., Gorgoulis, V. G., Vlachoyiannopoulos, P. G., & Tzioufas, A. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719023 · Cited by 37
Self-citationNormandin, E., Holroyd, K. B., Collens, S. I., Shaw, B. M., Siddle, K. J., Adams, G. C., Rudy, M. A., Solomon, I. H., Anahtar, M. N., Lemieux, J. E., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120023 · Cited by 37
Pathophysiology, diagnosis, and management of neuroinflammation in covid-19
Brown, R. L., Benjamin, L. A., Lunn, M. P., Bharucha, T., Zandi, M. S., Hoskote, C., McNamara, P., & Manji, H. (2023) · BMJ · doi:10.1136/bmj-2022-073923 · Cited by 37
Szabo, M. P., Iba, M., Nath, A., Masliah, E., & Kim, C. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00755-7 · Cited by 37
Neurovascular coupling impairment as a mechanism for cognitive deficits in COVID-19
Owens, C. D., Pinto, C. B., Detwiler, S., Olay, L., Pinaffi‐Langley, A. C. D. C., Mukli, P., Péterfi, A., Szarvas, Z., James, J. A., Galván, V., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae080 · Cited by 36
Lethal Pediatric Cerebral Vasculitis Triggered by Severe Acute Respiratory Syndrome Coronavirus 2
Poisson, K. E., Zygmunt, A., Leino, D. G., Fuller, C. E., Jones, B. V., Haslam, D. B., Staat, M. A., Clay, G. M., Ting, T. V., Wesselkamper, K., et al. (2021) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2021.11.003 · Cited by 34
Hsp90 inhibition protects the brain microvascular endothelium against oxidative stress
Uddin, M. A., Akhter, M. S., Kubra, K., Whitaker, K. E., Shipley, S. L., Smith, L. M., & Barabutis, N. (2021) · Brain Disorders · doi:10.1016/j.dscb.2020.100001 · Cited by 33
Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson’s Disease?
Krey, L., Huber, M. K., Höglinger, G. U., & Wegner, F. (2021) · Brain Sciences · doi:10.3390/brainsci11121654 · Cited by 31
Vraka, K., Ram, D., West, S., Chia, W. Y. E., Kurup, P., Subramanian, G., & Tan, H. J. (2021) · Case Reports in Neurological Medicine · doi:10.1155/2021/6658000 · Cited by 33
Cellular and Molecular Effects of SARS-CoV-2 Linking Lung Infection to the Brain
Francistiová, L., Klepe, A., Curley, G., Gulya, K., Dinnyés, A., & Filkor, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730088 · Cited by 36
Microglial Inflammatory Responses to SARS‐CoV‐2 Infection: A Comprehensive Review
Dey, R., & Bishayi, B. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01444-3 · Cited by 33
Neurochemical biomarkers to study CNS effects of COVID‐19: A narrative review and synthesis
Edén, A., Simrén, J., Price, R. W., Zetterberg, H., & Gisslén, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15459 · Cited by 29
SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation
MacDougall, M., Sleiman, J. E.-H., Beauchemin, P., & Rangachari, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871276 · Cited by 30
Mechanisms of viral persistence in the brain and therapeutic approaches
Nath, A., & Johnson, T. P. (2021) · FEBS Journal · doi:10.1111/febs.15871 · Cited by 26
Clinical, cerebrospinal fluid and neuroimaging findings in COVID-19 encephalopathy: a case series
Tuma, R., Guedes, B., Carra, R., Iepsen, B., Rodrigues, J., Camelo-Filho, A. E., Kubota, G., Ferrari, M., Neto, A. S., Oku, M. H. M., et al. (2020) · doi:10.1101/2020.08.28.20181883 · Cited by 26
Carod-Artal, F. J., & García‐Moncó, J. C. (2021) · Neurology Perspectives · doi:10.1016/j.neurop.2021.07.005 · Cited by 24
Consensus Clinical Guidance for Diagnosis and Management of Adult COVID-19 Encephalopathy Patients
Michael, B. D., Walton, D., Westenberg, E., García‐Azorín, D., Singh, B., Tamborska, A., Netravathi, M., Chomba, M., Wood, G. K., Easton, A., et al. (2021) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.22010002 · Cited by 26
Neurologic sequelae of COVID-19 are determined by immunologic imprinting from previous coronaviruses
Spatola, M., Nziza, N., Jung, W., Deng, Y., Yuan, D., Dinoto, A., Bozzetti, S., Chiodega, V., Ferrari, S., Lauffenburger, D. A., et al. (2023) · Brain · doi:10.1093/brain/awad155 · Cited by 25
Whitmore, H. A. B., & Kim, L. A. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.04.017 · Cited by 23
Post-COVID-19 encephalomyelitis
Kim, J., Abdullayev, N., Neuneier, J., Fink, G. R., & Lehmann, H. C. (2021) · Neurological Research and Practice · doi:10.1186/s42466-021-00113-4 · Cited by 21
Emerging Knowledge of the Neurobiology of COVID-19
Butler, M., Cross, B., Hafeez, D., Lim, M. F., Morrin, H., Rengasamy, E. R., Pollak, T. A., & Nicholson, T. R. (2021) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2021.11.001 · Cited by 20
Review of Neurological Manifestations of SARS-CoV-2
Priyal, P., Sehgal, V., Kapila, S., Taneja, R., Mehmi, P., & Gulati, N. (2023) · Cureus · doi:10.7759/cureus.38194 · Cited by 20
Aseptic meningitis after BNT-162b2 COVID-19 vaccination
Chan, A. C. Y., Tan, B. Y., Goh, Y., Tan, S. S., & Tambyah, P. A. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100406 · Cited by 20
Autoimmunity and SARS‐CoV‐2 infection: Unraveling the link in neurological disorders
Latorre, D. (2022) · European Journal of Immunology · doi:10.1002/eji.202149475 · Cited by 20
de Melo, I. S., Silva, R. S., Cunha, T. M., Goulart, L. R., Reis, W. L., Jardim, A. C. G., Shetty, A. K., & de Castro, O. W. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.008 · Cited by 21
Cheraghali, F., Tahamtan, A., Hosseini, S. A., Gharib, M. H., Moradi, A., Nikoo, H. R., & Tabarraei, A. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.565778 · Cited by 18
Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions
Qiu, Y., Mo, C., Chen, L., Ye, W., Chen, G., & Zhu, T. (2024) · MedComm · doi:10.1002/mco2.513 · Cited by 18
Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes
Chaumont, H., Kaczorowski, F., San‐Galli, A., Michel, P. P., Tressières, B., Roze, E. F., Quadrio, I., & Lannuzel, A. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.11.002 · Cited by 18
Cunningham, J. L., Virhammar, J., Rönnberg, B. J., Dopico, X. C., Kolstad, L., Albinsson, B., Kumlien, E., Nääs, A., Klang, A., Westman, G., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab153 · Cited by 17
Neurologic aspects of coronavirus disease of 2019 infection
Hassett, C. E., & Frontera, J. A. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000731 · Cited by 15
Neuroimaging Patterns in Patients with COVID-19-Associated Neurological Complications
Garg, R. K., Paliwal, V. K., Malhotra, H. S., & Sharma, P. K. (2021) · Neurology India · doi:10.4103/0028-3886.314531 · Cited by 14
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
Alexopoulos, H., Trougakos, I., Dimopoulos, M., & Terpos, E. (2022) · European journal of internal medicine · doi:10.1016/j.ejim.2022.11.009 · Cited by 14
Self-citationNersesjan, V., Amiri, M., Nilsson, A. C., Wamberg, C., Jensen, V. V. S., Petersen, C. B., Hejl, A., Lebech, A., Theut, A. M., Jørgensen, C. S., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad274 · Cited by 15
COVID‐19‐associated immune‐mediated encephalitis mimicking acute‐onset Creutzfeldt‐Jakob disease
Beretta, S., Stabile, A., Balducci, C., DiFrancesco, J. C., Patruno, A., Rona, R., Bombino, M., Capraro, C., Andreetta, F., Cavalcante, P., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51479 · Cited by 14
Neurological involvement in the respiratory manifestations of COVID-19 patients
Tan, B., Liu, J., Gui, Y., Wu, S., Suo, J., & Li, Y. (2021) · Aging · doi:10.18632/aging.202665 · Cited by 15
Kikinis, Z., Castañeyra-Perdomo, A., González–Mora, J. L., Rushmore, J., Toppa, P. H., Haggerty, K., Papadimitriou, G., Yogesh Rathi, A., Kubicki, M. R., Kikinis, R., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1337888 · Cited by 13
A Peek into Pandora’s Box: COVID-19 and Neurodegeneration
Chandra, A., & Johri, A. (2022) · Brain Sciences · doi:10.3390/brainsci12020190 · Cited by 14
SARS-CoV-2 infection and diabetes: Pathophysiological mechanism of multi-system organ failure
Roy, B., & Runa, S. A. (2022) · World Journal of Virology · doi:10.5501/wjv.v11.i5.252 · Cited by 12
Normal pressure hydrocephalus associated with COVID-19 infection: a case report
Vasconcelos, T. D. M. F., Nóbrega, P., Ferreira, G. D. M., de Souza, M. D., Vanderlei, A., de Castro, J. D., Braga-Neto, P., & Sobreira-Neto, M. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-022-07184-x · Cited by 8
Blood-brain Barrier Damage is Pivotal for SARS-CoV-2 Infection to the Central Nervous System
Rodríguez-Morales, J., Guartazaca-Guerrero, S., Rizo-Téllez, S. A., Viurcos-Sanabria, R., Barrón-Palma, E. V., Valencia, A. F. H., Nava, P., Escobedo, G., Carrillo-Ruiz, J. D., & Méndez-García, L. A. (2022) · Experimental Neurobiology · doi:10.5607/en21049 · Cited by 11
Reemerging Infectious Diseases and Neuroimmunologic Complications
Nath, A., & Kolson, D. L. (2024) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200356 · Cited by 10
Borsche, M., Reichel, D., Fellbrich, A., Lixenfeld, A. S., Rahmöller, J., Vollstedt, E., Föh, B., Balck, A., Klein, C., Ehlers, M., et al. (2021) · Neurological Research and Practice · doi:10.1186/s42466-021-00135-y · Cited by 10
Blood-brain barrier breakdown in COVID-19 ICU survivors: an MRI pilot study
Shi, W., Jiang, D., Rando, H. J., Khanduja, S., Lin, Z., Hazel, K., Pottanat, G., Jones, E., Xu, C., Lin, D. D. M., et al. (2023) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2023-0018 · Cited by 14
Muñoz-Jurado, A., Escribano, B. M., Agüera, E., Caballero‐Villarraso, J., Galván, A., & Túnez, I. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11237-1 · Cited by 10
The Impact of the COVID-19 Virus Pandemic on the Incidence of First Psychotic Spectrum Disorders
Łoś, K., Kulikowska, J., & Waszkiewicz, N. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19073781 · Cited by 9
Brain stem encephalitis is a rare complication of COVID-19
Shamier, M. C., Crijnen, Y. S., Bogers, S., IJpelaar, J., de Vries, J. M., van der Jagt, M., Spoor, J. K. H., von der Thüsen, J. H., Schreurs, M. W. J., GeurtsvanKessel, C. H., et al. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.578007 · Cited by 9
Modulation of Paracellular Permeability in SARS-CoV-2 Blood-to-Brain Transcytosis
Martinez, T. E., Mayilsamy, K., Mohapatra, S. S., & Mohapatra, S. (2024) · Viruses · doi:10.3390/v16050785 · Cited by 9
Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment
Oba, S., Hosoya, T., Iwai, H., & Yasuda, S. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2570902 · Cited by 11
Hachem, M. (2021) · Biochimie · doi:10.1016/j.biochi.2021.02.012 · Cited by 8
Pathophysiology of COVID-19-Associated Neurotoxicity
Cascella, M., & Blasio, E. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-86705-8_1 · Cited by 8
Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?
Bauer, L., & van Riel, D. A. J. (2023) · mBio · doi:10.1128/mbio.02920-22 · Cited by 9
van Reekum, E. A., Rosic, T., Sergeant, A., Sanger, N., Rodrigues, M., Rebinsky, R., Panesar, B., Deck, E., Kim, N., Woo, J., et al. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-03140-6 · Cited by 8
Omidian, N., Mohammadi, P., Sadeghalvad, M., & Mohammadi‐Motlagh, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113534 · Cited by 9
Sivagurunathan, N., & Latchoumycandane, C. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230418114446 · Cited by 8
Pacnejer, A.-M., Butucă, A., Dobrea, C. M., Arseniu, A. M., Frum, A., Gligor, F. G., Arseniu, R., Vonica, R. C., Vonica-Țincu, A. L., Oancea, C. I., et al. (2024) · Viruses · doi:10.3390/v16121811 · Cited by 8
Kulikowska, J., Kulczyńska‐Przybik, A., Mroczko, B., & Kułakowska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115894 · Cited by 7
COVID-19 – prime time for microphysiological systems, as illustrated for the brain
Kang, I. (2021) · ALTEX · doi:10.14573/altex.2110131 · Cited by 6
Neurological complications of COVID-19 in elderly people
Nikitina, A. Y., Chimagomedova, A. S., & Levin, O. S. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20211211025 · Cited by 6
Peripheral neuropathies during the COVID-19 pandemic: is there a relation?
Trentinaglia, M., Lippi, G., Salvagno, G. L., Rispoli, M. G., Angelis, M. V. D., Castellani, F., Alberti, D., Maniscalco, G. T., Rossi, F., Turri, M., et al. (2022) · Immunologic Research · doi:10.1007/s12026-022-09272-1 · Cited by 6
Wang, J. Y., Zhang, W., Roehrl, M. H. A., Roehrl, M. H. A., & Roehrl, M. H. A. (2023) · Australian Journal of Chemistry · doi:10.1071/ch22268 · Cited by 6
Oliveira, K. B., de Melo, I. S., da Silva, B. R. M., Oliveira, K. L. D. S., Silva, R. S., Anhezini, L., Katayama, P. L., Santos, V. R., Shetty, A. K., & de Castro, O. W. (2023) · Neuroscience Insights · doi:10.1177/26331055231151926 · Cited by 6
Is there a difference between GBS triggered by COVID-19 and those of other origins?
Radišić, V., Ždraljević, M., Perić, S., Mladenović, B., Ralić, B., Jovanovic, D. R., & Berisavac, I. (2022) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-022-00486-6 · Cited by 5
Neuro–Immune Interactions in Severe COVID-19 Infection
Rossi, E. G., Mutti, L., Morrione, A., & Giordano, A. (2022) · Pathogens · doi:10.3390/pathogens11111256 · Cited by 7
Hypertonic Solution in Severe COVID-19 Patient: A Potential Adjuvant Therapy
Gennari-Felipe, M., Borges, L., Dermargos, A., Weimann, E., Curi, R., Pithon‐Curi, T. C., & Hatanaka, E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.917008 · Cited by 4
Massa, F., Vigo, T., Bellucci, M., Giunti, D., Mobilia, E. M., Visigalli, D., Capodivento, G., Cerne, D., Assini, A., Boni, S., et al. (2024) · Neurological Sciences · doi:10.1007/s10072-023-07279-6 · Cited by 5
Walton, D., Thakur, K. T., Venkatesan, A., Breen, G. D., Solomon, T., & Michael, B. D. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.637586 · Cited by 4
COVID-19 Infection Presenting With Severe Hydrocephalus and Acute Stroke: A Case Report
Oredipe, O., Johal, A. S., Onuegbu, C. A., Kalejaiye, A., Okoye, C., Pozdniakova, H., Udongwo, N., & Patel, S. (2022) · Cureus · doi:10.7759/cureus.30592 · Cited by 4
The anti-COVID-19 drug Paxlovid crosses biological barriers of the placenta and brain in rats
Lee, W.-H., Sun, C., Chang, C., Yang, M., & Tsai, T. (2024) · npj Viruses · doi:10.1038/s44298-023-00013-1 · Cited by 4
Xu, J., Wei, H., You, P., Sui, J., Xiu, J., Zhu, W., & Xu, Q. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1177961 · Cited by 3
Hamed, S. A. (2023) · World Journal of Otorhinolaryngology · doi:10.5319/wjo.v10.i2.4 · Cited by 3
Acute Ataxia and Myoclonus in COVID-19
Sundar, U. S., Shah, M. H., Merchant, S. A., & Asole, D. C. (2021) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_1296_20 · Cited by 3
Chronic fatigue syndrome against the background of the COVID-19 pandemic
Nikitina, A. Y., & Levin, O. S. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112110292 · Cited by 3
Neuropsychiatric complications of coronavirus disease 2019: Mount Sinai Health System cohort study
Gururangan, K., Peschansky, V. J., Hyfte, G. V., Agarwal, P., Blank, L. J., Mathew, B., Goldstein, J. M., Kwon, C., McCarthy, L., Cohen, A., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12370-9 · Cited by 2
Metadata
- Authors
- Alexopoulos, H., Magira, E., Bitzogli, K., Kafasi, N., Vlachoyiannopoulos, P., Tzioufas, A., Kotanidou, A., & Dalakas, M. C.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- From the Neuroimmunology Unit (H.A., K.B., M.C.D.), Department of Pathophysiology (P.V., A.T.), and 1st Department of Intensive Care Medicine (E.M., A.K.), Evangelismos Hospital, Faculty of Medicine, National and Kapodistrian University of Athens; and Department of Immunology and Histocompatibility (N.K.), Laikon University Hospital, Athens, Greece.
- Corresponding author
- Dalakas, Marinos C.
- ORCID
- Venue
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2020-11
- Volume
- 7
- Issue
- 6
- ISSN
- 2332-7812 (ISSN-L)
- PMC
- PMC7577546
- OpenAlex
- W3089322801
- Cited by
- 131
- References
- 12
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 14 · 2023: 20 · 2022: 31 · 2021: 51 · 2020: 6
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology Neuroimmunology & Neuroinflammation (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- COVID-19 pandemic, SARS-CoV-2, SARS-CoV-2 antibodies, cerebrospinal fluid, blood-brain barrier dysfunction, intrathecal IgG synthesis, encephalopathy, prolonged coma, 14-3-3 proteins, neurodegeneration, neuroinflammation, albumin index
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Aged, Aged, 80 and over, Autoantibodies, Blood-Brain Barrier, Coma, Female, Humans, Male, Middle Aged, Nervous System Diseases, Pneumonia, Viral, Biomarkers, Treatment Outcome, Coronavirus Infections, Stupor, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
